Clinical Trials
31
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (30 trials with phase data)• Click on a phase to view related trials
A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).
- Conditions
- Fibrodysplasia Ossificans Progressiva
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Clementia Pharmaceuticals Inc.
- Target Recruit Count
- 98
- Registration Number
- NCT05039515
- Locations
- 🇺🇸
University of California San Francisco (UCSF), San Francisco, California, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult Subjects
- Conditions
- Fibrodysplasia Ossificans Progressiva
- Interventions
- First Posted Date
- 2021-04-02
- Last Posted Date
- 2021-04-02
- Lead Sponsor
- Clementia Pharmaceuticals Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT04829773
- Locations
- 🇺🇸
Cambridge Ipsen US, Cambridge, Massachusetts, United States
Study to Compare the Pharmacokinetics, Safety, and Tolerability Following Administration of Palovarotene in Healthy Japanese and Non-Asian Subjects
- First Posted Date
- 2021-04-02
- Last Posted Date
- 2021-04-02
- Lead Sponsor
- Clementia Pharmaceuticals Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT04829786
Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Palovarotene Ophthalmic Solution in Healthy Adult Subjects
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Clementia Pharmaceuticals Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT04762355
- Locations
- 🇨🇦
Algorithme Pharma facility, Québec, Canada
An Efficacy and Safety Study of Palovarotene for the Treatment of MO
- Conditions
- Exostoses, Multiple Hereditary
- Interventions
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2022-08-01
- Lead Sponsor
- Clementia Pharmaceuticals Inc.
- Target Recruit Count
- 193
- Registration Number
- NCT03442985
- Locations
- 🇺🇸
Children's Orthopaedic Center, Los Angeles, California, United States
🇺🇸Shriners Hospital for Children - Sacramento, Sacramento, California, United States
🇺🇸University of California-San Francisco, San Francisco, California, United States
- Prev
- 1
- 2
- Next